ATE521366T1 - Anwendung von amatoxin-konjugaten und phallotoxin-konjugaten mit makromolekülen zur krebstherapie und therapie von entzündungen - Google Patents

Anwendung von amatoxin-konjugaten und phallotoxin-konjugaten mit makromolekülen zur krebstherapie und therapie von entzündungen

Info

Publication number
ATE521366T1
ATE521366T1 AT06010902T AT06010902T ATE521366T1 AT E521366 T1 ATE521366 T1 AT E521366T1 AT 06010902 T AT06010902 T AT 06010902T AT 06010902 T AT06010902 T AT 06010902T AT E521366 T1 ATE521366 T1 AT E521366T1
Authority
AT
Austria
Prior art keywords
conjugates
therapy
inflammation
macromolecles
phallotoxin
Prior art date
Application number
AT06010902T
Other languages
English (en)
Inventor
Heinz Faulstich
Dorian Faulstich
Jan Dr Anderl
Gerhard Dr Moldenhauer
Original Assignee
Faulstich Heinz Dr
Deutsches Krebsforsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faulstich Heinz Dr, Deutsches Krebsforsch filed Critical Faulstich Heinz Dr
Application granted granted Critical
Publication of ATE521366T1 publication Critical patent/ATE521366T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT06010902T 2006-05-27 2006-05-27 Anwendung von amatoxin-konjugaten und phallotoxin-konjugaten mit makromolekülen zur krebstherapie und therapie von entzündungen ATE521366T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06010902A EP1859811B1 (de) 2006-05-27 2006-05-27 Anwendung von Amatoxin-Konjugaten und Phallotoxin-Konjugaten mit Makromolekülen zur Krebstherapie und Therapie von Entzündungen

Publications (1)

Publication Number Publication Date
ATE521366T1 true ATE521366T1 (de) 2011-09-15

Family

ID=37081660

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06010902T ATE521366T1 (de) 2006-05-27 2006-05-27 Anwendung von amatoxin-konjugaten und phallotoxin-konjugaten mit makromolekülen zur krebstherapie und therapie von entzündungen

Country Status (3)

Country Link
EP (1) EP1859811B1 (de)
AT (1) ATE521366T1 (de)
ES (1) ES2371085T3 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014208301A1 (en) * 2009-04-08 2014-08-21 Deutsches Krebsforschungszentrum Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy
MX2011010469A (es) 2009-04-08 2012-03-14 Deutsches Krebsforsch Radicales de enlace al objetivo, armados con amatoxina para el tratamiento del cancer.
EP3192529B1 (de) 2009-04-08 2020-03-25 Faulstich, Heinz, Dr. Amatoxinbestückte, zur tumortherapie designte therapiezellenoberflächenbindungskomponente
ES2402254T3 (es) 2010-09-30 2013-04-30 Heidelberg Pharma Ag Conjugados de amatoxinas con ligadores mejorados
EP2497499A1 (de) 2011-03-10 2012-09-12 Heidelberg Pharma GmbH Amatoxinkonjugate mit verbesserten Verknüpfungen
CA2858806A1 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of polypeptides
EP2872894B1 (de) 2012-07-13 2019-04-17 Innate Pharma Screening von konjugierten antikörpern
EP2684865A1 (de) 2012-07-13 2014-01-15 Heidelberg Pharma GmbH Verfahren zum Synthetisieren eines Amatoxinbausteins und von Amatoxinen
EP2916872B1 (de) 2012-11-09 2019-02-27 Innate Pharma Kennungen für tgase-vermittelte konjugation
EP2774624A1 (de) 2013-03-04 2014-09-10 Heidelberg Pharma GmbH Amatoxinderivate
US10611824B2 (en) 2013-03-15 2020-04-07 Innate Pharma Solid phase TGase-mediated conjugation of antibodies
WO2014202773A1 (en) 2013-06-20 2014-12-24 Innate Pharma Enzymatic conjugation of polypeptides
KR20160042871A (ko) 2013-06-21 2016-04-20 이나뜨 파르마, 에스.아. 폴리펩티드의 효소적 콘쥬게이션
EP3215519A1 (de) 2014-11-06 2017-09-13 Novartis AG Amatoxinderivate und konjugate davon als inhibitoren der rna-polymerase
DK3268047T3 (da) 2015-03-09 2024-01-02 Heidelberg Pharma Res Gmbh Amatoxin/antistof-konjugater
US10723766B2 (en) 2015-11-27 2020-07-28 Heidelberg Pharma Research Gmbh Derivatives of gamma-amanitin
EP3222292A1 (de) 2016-03-03 2017-09-27 Heidelberg Pharma GmbH Amanitinkonjugate
US10464969B2 (en) 2016-05-05 2019-11-05 Novartis Ag Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase
US10111966B2 (en) 2016-06-17 2018-10-30 Magenta Therapeutics, Inc. Methods for the depletion of CD117+ cells
CN109641051A (zh) 2016-06-17 2019-04-16 美真达治疗公司 用于耗尽细胞的组合物和方法
BR112019012937A2 (pt) * 2016-12-23 2019-12-10 Heidelberg Pharma Research Gmbh novo conjugado de amanitina
SG11201906319XA (en) 2017-01-20 2019-08-27 Magenta Therapeutics Inc Compositions and methods for the depletion of cd137+ cells
CN110997676B (zh) 2017-08-07 2022-12-20 海德堡医药研究有限责任公司 合成鹅膏蕈碱的新方法
CA3066867A1 (en) 2017-08-07 2019-02-14 Heidelberg Pharma Research Gmbh Novel method for synthesizing amanitins
WO2019057964A1 (en) 2017-09-22 2019-03-28 Heidelberg Pharma Research Gmbh AMANITINE CONJUGATES TARGETING PSMA
US10882915B2 (en) 2017-10-24 2021-01-05 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD117+ cells
EP3700568A4 (de) 2017-10-24 2021-11-10 Magenta Therapeutics, Inc. Zusammensetzungen und verfahren zur abreicherung von cd117+-zellen
WO2019092148A1 (en) 2017-11-10 2019-05-16 Innate Pharma Antibodies with functionalized glutamine residues
AU2018374283B2 (en) 2017-11-29 2025-09-18 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD5+ cells
CN110170057A (zh) * 2019-04-08 2019-08-27 嘉兴市第二医院 一种Tf修饰的负载双药的纳米颗粒制备方法及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925648A (en) * 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
WO1990009799A1 (en) * 1989-02-23 1990-09-07 Colorado State University Research Foundation GnRH ANALOGS FOR DESTROYING GONADOTROPHS
DE19514088A1 (de) * 1995-04-13 1996-10-17 Deutsches Krebsforsch Konjugat zur Behandlung von Entzünduns-, Infektions- und/oder Hauterkrankungen
BR122019027966B8 (pt) * 2002-05-02 2021-07-27 Wyeth Corp conjugado monomérico de derivado de caliqueamicina/anti-corpo anti-cd22 e uso dos mesmos
WO2004043461A1 (en) * 2002-11-06 2004-05-27 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome

Also Published As

Publication number Publication date
EP1859811A1 (de) 2007-11-28
ES2371085T3 (es) 2011-12-27
EP1859811B1 (de) 2011-08-24

Similar Documents

Publication Publication Date Title
CY1124166T1 (el) Συζευγματα αντισωματος φαρμακου (adc) τα οποια δεσμευονται σε 191p4d12 πρωτεϊνες
ATE472338T1 (de) Anti-cd70 antikörper-arzneimittelkonjugate und ihre verwendung zur behandlung von krebs
DE602006016344D1 (de) Für das fibroblastenaktivierungsprotein spezifische antikörpermoleküle und immunkonjugate, die diese enthalten
NO20083891L (no) Anti-5T4 antistoffer og anvendelser derav
AR069903A1 (es) Conjugado anticuerpo- molecula asociada dirigidos a la proteina tirosina quinasa 7 (ptk 7), composicion farmaceutica que lo comprende, acido nucleico, factor de expresion y celula huesped relacionados y su uso para preparar un medicamento util para el tratamiento o prevencion de cancer
AR067995A1 (es) Acoplamiento en sitio especifico de farmacos u otros agentes a anticuerpos disenados con extensiones c-terminales
BRPI0511755A (pt) composições, fusões e conjugados de drogas e métodos de produção, tratamento e utilização
DK1629011T3 (da) Humane anti-humane-DC3-bindingsmolekyler
CY1117331T1 (el) Αντισωματα προσδεσης στην εξωκυτταρικη περιοχη 4 του ανθρωπινου csf1r και η χρηση αυτων
BR112012026213A2 (pt) pirrolobenzodiazepinas e conjugados das mesmas
CY1110783T1 (el) Μονοκλωνικα αντισωματα κατα αυξητικου παραγοντα ηπατοκυτταρων
ATE414106T1 (de) Pegylierte single-domain-antikörper (dab)
CY1118369T1 (el) Αντισωματα εναντι cd38 για την θεραπεια πολλαπλου μυελωματος
CO6630164A2 (es) Proteinas que se unen al tnf-a
EP4461318A3 (de) Neuartige antikörper-wirkstoff-konjugate gegen prostataspezifisches membranantigen (psma)
CY1115147T1 (el) Εξουδετερωτικα αντισωματα που εχουν ειδικοτητα για ανθρωπινη il-17
CY1116264T1 (el) Αντισωματα κατα ανθρωπινης αγγειοποιητινης 2
AR035977A1 (es) Inmunoconjugados de anticuerpos cd44 citotoxicos.
AR069747A1 (es) Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
CL2022003715A1 (es) Tubulisinas y conjugados de proteinas-tubulisina
ATE395082T1 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
MX2009009926A (es) Anticuerpo tumor-especifico humano monoclonal.
ATE442861T1 (de) Gegen antikörper gerichtete photodynamische therapie
DE602006019977D1 (de) Therapie mit anti-cd4-antikörpern und bestrahlung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties